Sign inCreate account

Report workspace tools

NCT04514510COMPLETEDanonymous

A Study to Evaluate the Effects of Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease

Sponsor

Source record

National Heart, Lung, and Blood Institute (NHLBI)

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Sickle Cell Disease

Indication / condition

AI-normalized

Sickle Cell Disease

Intervention

Source record

Isoquercetin, Placebo

Source & freshness

Source record

NCT ID

NCT04514510

Original source

ClinicalTrials.gov

Source last updated

Jan 02, 2024

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04514510

Title

A Study to Evaluate the Effects of Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Status

COMPLETED

Phase

Phase 2

Condition raw

Sickle Cell Disease

Condition normalized

Sickle Cell Disease

Modality raw

Sickle Cell Disease

Modality normalized

small molecule

Target raw

Sickle Cell Disease

Target normalized

Sickle Cell Disease

Interventions

Isoquercetin, Placebo

Public preview

Source record

This clinical trial evaluated the effects of isoquercetin, a dietary supplement, on thrombo-inflammatory biomarkers in adults with stable sickle cell disease (SCD). The study aimed to determine if isoquercetin could reduce inflammation and blood clotting, potentially improving patient outcomes.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Study to Evaluate the Effects of Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04514510

Status

COMPLETED

Phase

Phase 2

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Executive brief

Investment-Ready Snapshot

This clinical trial evaluated the effects of isoquercetin, a dietary supplement, on thrombo-inflammatory biomarkers in adults with stable sickle cell disease (SCD). The study aimed to determine if isoquercetin could reduce inflammation and blood clotting, potentially improving patient outcomes.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 02, 2024
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04514510

Indication

Sickle Cell Disease

Modality

small molecule

Target

Sickle Cell Disease

Intervention

Isoquercetin, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.